SV Health Investors
Overview
SV Health Investors is a global private equity and venture capital investment firm exclusively dedicated to the healthcare sector, investing across diverse stages and sub-sectors including biotechnology, healthcare growth equity, and medtech.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Adimab | Apr 2012 | Series F | Co-investor |
| Evidation | Jul 2020 | Series D | Co-investor |
| BioAge Labs | Feb 2024 | Series D | Co-investor |
| OMass Therapeutics | Oct 2026 | Series C | Co-investor |
| AviadoBio | Dec 2021 | Series A | Co-investor |
For institutional investors. Book with your work email.
Key People
Eugene Hill
Managing Partner
Greg Madden
Managing Partner
Gregory Madden
Managing Partner
Kate Bingham
Managing Partner
Michael Balmuth
Managing Partner
Nikola Trbovic
Managing Partner
Paul LaViolette
Managing Partner
Tom Flynn
Managing Partner
Mike Ross
Senior Partner
Ali Jazayeri
Operating Partner
Luke Johnson
Operating Partner
Brett Haumann
Venture Partner
Charles Large
Venture Partner
Forbes Huang
Venture Partner
Hamish Cameron
Venture Partner
Iain Kilty
Venture Partner
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is SV Health Investors based?
SV Health Investors is headquartered in Boston, Massachusetts, United States.
When was SV Health Investors founded?
SV Health Investors was founded in 1993.
How many portfolio companies does SV Health Investors have?
SV Health Investors has 75 portfolio companies in Caplight's dataset.
What are some companies in SV Health Investors's portfolio?
Portfolio companies visible on Caplight include Adimab, Evidation, BioAge Labs, OMass Therapeutics, AviadoBio.
What was SV Health Investors's most recent investment shown here?
SV Health Investors's most recent investment in this portfolio sample was in OMass Therapeutics in 2026.
What sectors does SV Health Investors focus on?
SV Health Investors focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, FinTech, Healthcare & Life Sciences, FinTech, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software, AI, Data & Cloud Infrastructure, Enterprise Software, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does SV Health Investors focus on?
SV Health Investors typically invests at the MultiStage stage.
What is SV Health Investors's AUM?
SV Health Investors's assets under management are estimated between $3.7B and $4.0B.